Core Viewpoint - The performance of Haemonetics' international operations is crucial for assessing its financial resilience and growth prospects, especially in the context of a highly interconnected global economy [2][3]. Group 1: Financial Performance Overview - For the quarter ended December 2025, Haemonetics reported total revenue of $338.97 million, reflecting a decline of 2.8% year over year [4]. - The company is projected to achieve total revenue of $1.32 billion for the full year, indicating a fall of 2.6% from the previous year [9]. Group 2: International Revenue Breakdown - Japan contributed $18.14 million, or 5.4% of total revenue, with a surprise increase of +1.87% compared to analyst expectations [5]. - Europe generated $48.28 million, accounting for 14.2% of total revenue, surpassing projections by +6.65% [6]. - Other International regions contributed $1.81 million, making up 0.5% of total revenue, which was a decline of -22.23% from expectations [7]. Group 3: Future Revenue Expectations - Analysts anticipate revenues of $336.54 million for the current fiscal quarter, representing an increase of 1.8% year over year [8]. - Expected revenue contributions for the current quarter are projected to be 5.6% from Japan ($18.94 million), 13.5% from Europe ($45.38 million), and 1.2% from Other International ($3.93 million) [8].

Core Viewpoint - Haemonetics Corporation reported strong earnings for Q3, exceeding analyst expectations in both earnings per share and sales figures, despite a subsequent decline in share price [1]. Financial Performance - The company reported quarterly earnings of $1.31 per share, surpassing the analyst consensus estimate of $1.25 per share [1]. - Quarterly sales reached $338.967 million, exceeding the analyst consensus estimate of $331.616 million [1]. - Haemonetics raised its FY2026 adjusted EPS guidance from a range of $4.80-$5.00 to $4.90-$5.00 [1]. Stock Performance - Following the earnings announcement, Haemonetics shares fell by 6%, trading at $61.13 [1]. Analyst Ratings and Price Targets - Barrington Research analyst Michael Petusky maintained an Outperform rating on Haemonetics and raised the price target from $93 to $94 [3]. - Mizuho analyst Anthony Petrone also maintained an Outperform rating but lowered the price target from $90 to $80 [3].

Company Overview - Haemonetics Corporation provides blood management solutions to blood and plasma collectors, hospitals, and healthcare providers globally, offering integrated devices, information management, and consulting services to enhance clinical outcomes in the blood supply chain [11]. Investment Potential - Haemonetics is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of A, indicating a solid investment potential [12]. - The company has a Growth Style Score of B, forecasting a year-over-year earnings growth of 8.1% for the current fiscal year, with a recent upward revision in earnings estimates [12]. - The Zacks Consensus Estimate for Haemonetics has increased by $0.01 to $4.94 per share, and the company has an average earnings surprise of +6.8% [12]. Recommendation - With a strong Zacks Rank and favorable Growth and VGM Style Scores, Haemonetics is recommended for investors looking for growth opportunities [13].

Core Insights - Haemonetics Corporation (HAE) reported third-quarter fiscal 2026 adjusted earnings per share (EPS) of $1.31, reflecting a year-over-year increase of 10.1% and exceeding the Zacks Consensus Estimate by 3.1% [1][9] - The company's revenues decreased by 2.7% to $339 million, which still surpassed the Zacks Consensus Estimate by 1.4% [2][9] Revenue Breakdown - Plasma segment revenues reached $138.9 million, up 3.5% year over year, with organic growth of 2.8%, driven by strong demand for immunoglobulin [3] - Blood Center revenues fell 19.6% to $56.6 million, although organic growth was 2.8%, supported by international Plasma demand [4] - Hospital revenues slightly decreased by 0.3% to $143.5 million, with a 0.9% decline on an organic basis [4] Margin Performance - Gross profit increased by 4.6% to $202.4 million, with gross margin expanding by 418 basis points to 59.7% due to an 11.9% decline in the cost of sales [6] - Operating profit rose to $79 million, compared to $71.3 million in the prior year, with an operating margin increase of 287 basis points to 23.3% [7][9] Financial Position - At the end of the third quarter, Haemonetics had cash and cash equivalents of $363.4 million, up from $296.4 million at the end of the previous quarter [8] - Long-term debt remained stable at $920 million, and cumulative net cash flow from operating activities increased to $222.3 million from $65.2 million a year ago [8] Guidance - The company now expects fiscal 2026 GAAP revenues to decline by 1-3%, with organic revenue growth anticipated in the range of 0-2% compared to fiscal 2025 [10] - Adjusted EPS guidance for full-year 2026 is set between $4.90 and $5.00, up from the previous range of $4.80 to $5.00 [11] Overall Assessment - Haemonetics demonstrated better-than-expected results in the fiscal third quarter, with earnings and revenues surpassing estimates despite a year-over-year revenue decline [12] - The performance highlights the strength of the company's core businesses, particularly in Blood Management Technologies and Plasma, while targeted actions are planned to improve Interventional Technologies [12][13]

Financial Data and Key Metrics Changes - Third quarter revenue was $339 million, bringing year-to-date revenue to $988 million, with reported revenue reflecting a $153 million impact from last year's portfolio transitions [5][6] - Adjusted earnings per share increased 10% in the quarter to $1.31 and 11% year-to-date to $3.67, indicating strong earnings quality and durability [6][16] - Adjusted gross margin was 60.2% in the third quarter, up 250 basis points year-over-year, and 60.5% year-to-date, up 390 basis points [13][14] - Free cash flow for the third quarter was $74 million, bringing year-to-date free cash flow to $165 million, representing a more than threefold increase compared to the prior year [17][18] Business Line Data and Key Metrics Changes - Hospital revenue was $144 million in the third quarter, down 1% but up 2% year-to-date organically, with strong performance in Blood Management Technologies offsetting softness in Interventional Technologies [6][9] - Blood Management Technologies grew 8% in the quarter and 11% year-to-date, driven by strong sales of TEG 6s disposables and the heparinase neutralization cartridge [6][7] - Interventional Technology revenue declined 12% in the quarter and 8% year-to-date, primarily due to softness in esophageal cooling and OEM-related headwinds [8][9] - Plasma revenue was $139 million, up 3% on a reported basis, with organic growth of 20% in the quarter and 22% year-to-date, driven by share gains and collection volume [9][10] Market Data and Key Metrics Changes - U.S. plasma collections grew in the low double digits in the third quarter, with the company holding approximately 50% global market share [10] - Blood Center revenue was $57 million in the quarter, growing 3% in the quarter and 4% year-to-date organically, driven by international plasma demand [10][11] Company Strategy and Development Direction - The company is focused on returning the Interventional Technologies franchise to sustainable growth in fiscal 2027, with targeted actions underway to strengthen execution [20][21] - The acquisition of Vivasure is expected to enhance the company's leadership in vascular closure, with a $300 million addressable market identified [43][46] - Capital allocation priorities include investing in organic growth, meeting debt obligations, and opportunistically returning cash to shareholders while maintaining balance sheet flexibility [22][46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the plasma business, highlighting strong share gains and favorable market conditions [25][27] - The company anticipates continued margin expansion, although future increments may be smaller than those seen in fiscal 2026 [30][31] - Management remains optimistic about the growth potential in the vascular closure market, particularly with the anticipated MVP XL label expansion [38][59] Other Important Information - The company raised its full-year revenue guidance to a decline of 1%-3%, reflecting improved performance across Plasma, Blood Center, and Blood Management Technologies [11] - Adjusted operating income increased 4% year-to-date to $254 million, with adjusted operating margin expanding 200 basis points to 25.7% [15] Q&A Session Summary Question: Insights on plasma growth and sustainability - Management highlighted strong share gains and collection volume growth, indicating a favorable outlook for plasma in fiscal 2027 [25][27] Question: Margin expectations and challenges in the hospital business - Management acknowledged a sequential decline in adjusted operating margin but expressed confidence in overall margin expansion moving forward [30][31] Question: Updates on the IVT business and competition - Management noted that a significant portion of the decline in IVT was due to specific market dynamics, but they are confident in their strategy to return to growth [36][38] Question: Details on the Vivasure acquisition and market positioning - Management emphasized the strategic importance of Vivasure in enhancing their vascular closure portfolio and outlined a measured approach to its market launch [43][46] Question: Sustainability of blood center growth - Management indicated that while the blood center business has shown positive growth, it is subject to order timing and market conditions [79]

Financial Data and Key Metrics Changes - Third quarter revenue was $339 million, bringing year-to-date revenue to $988 million, with reported revenue reflecting a $153 million impact from last year's portfolio transitions [5][6] - Adjusted earnings per share increased 10% in the quarter to $1.31 and 11% year-to-date to $3.67, indicating strong earnings quality and durability [6][16] - Adjusted gross margin was 60.2% in the third quarter, up 250 basis points year-over-year, and 60.5% year-to-date, up 390 basis points [13][14] - Free cash flow for the third quarter was $74 million, bringing year-to-date free cash flow to $165 million, representing a more than threefold increase compared to the prior year [18][19] Business Line Data and Key Metrics Changes - Hospital revenue was $144 million in the third quarter, down 1% but up 2% year-to-date organically, with blood management technologies growing 8% in the quarter [6][9] - Plasma revenue was $139 million, up 3% on a reported basis, with organic growth excluding CSL at 20% in the quarter [9][10] - Blood Center revenue was $57 million in the quarter, growing 3% and 4% year-to-date organically, driven by international plasma demand [10][11] Market Data and Key Metrics Changes - U.S. plasma collections grew in the low double digits in the third quarter, with the company holding approximately 50% global market share [10] - The vascular closure market is experiencing headwinds from increasing PFA adoption, which is affecting growth rates in the electrophysiology market [58][60] Company Strategy and Development Direction - The company is focused on returning the interventional technologies franchise to sustainable growth in fiscal 2027, with targeted actions underway to strengthen execution [20][21] - The acquisition of Vivisure is expected to enhance the company's position in vascular closure, with a market potential of approximately $300 million [44][48] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the plasma business, citing strong share gains and favorable market conditions [25][27] - The company anticipates continued margin expansion, although future increments may be smaller than those seen in fiscal 2026 [30][32] Other Important Information - The company raised its full-year revenue guidance, expecting a decline of 1%-3% from a previous range of 1%-4% [11] - Cash on hand at the end of the third quarter was $363 million, up 18% since the start of the fiscal year [19] Q&A Session Summary Question: Insights on plasma growth and sustainability - Management highlighted strong share gains and collection volume growth, indicating a favorable outlook for plasma in fiscal 2027 [25][27] Question: Margin outlook and hospital business challenges - Management acknowledged a sequential decline in adjusted operating margin but expressed optimism about stabilization in the hospital business [28][30] Question: IVT business recovery and competition - Management noted that a significant portion of the decline in IVT was due to specific product disruptions, but they are confident in returning to growth [36][38] Question: Vivisure acquisition details - Management emphasized the strategic importance of Vivisure and its potential to enhance the vascular closure portfolio [44][48] Question: Capital deployment strategy - Management outlined a disciplined approach to capital deployment, prioritizing organic growth and debt reduction while maintaining flexibility for future investments [47][48]

Financial Data and Key Metrics Changes - Third quarter revenue was $339 million, bringing year-to-date revenue to $988 million, with reported revenue reflecting a $153 million impact from last year's portfolio transitions [4][10] - Adjusted earnings per share increased 10% in the quarter to $1.31 and 11% year-to-date to $3.67, indicating strong earnings quality and durability [5][14] - Adjusted gross margin was 60.2% in the third quarter, up 250 basis points year-over-year, driven by the adoption of NexSys technology and divestiture of the Whole Blood business [11][12] - Free cash flow for the third quarter was $74 million, with year-to-date free cash flow reaching $165 million, representing a threefold increase compared to the prior year [15][16] Business Line Data and Key Metrics Changes - Hospital revenue was $144 million in the third quarter, down 1% but up 2% year-to-date organically, with blood management technologies growing 8% in the quarter [5][6] - Plasma revenue was $139 million, up 3% on a reported basis, with organic growth of 20% in the quarter, driven by share gains and collection volume [8][9] - Blood Center revenue was $57 million in the quarter, growing 3% organically, primarily due to international plasma demand [9][10] Market Data and Key Metrics Changes - U.S. plasma collections grew in the low double digits in the third quarter, with the company holding approximately 50% global market share [8][9] - The hospital business is expected to deliver reported and organic growth of approximately 4% at the low end of the prior 4%-7% range [7][10] Company Strategy and Development Direction - The company is focused on returning the Interventional Technologies franchise to sustainable growth in fiscal 2027, with targeted actions underway to strengthen this segment [18][19] - The Vivisure acquisition is expected to enhance the company's leadership in vascular closure, with a market opportunity estimated at $300 million [44][47] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the plasma business, highlighting strong relationships and a favorable market environment [24][26] - The company anticipates continued margin expansion and strong cash flow generation, with a focus on disciplined capital deployment [15][21] Other Important Information - Adjusted operating income increased 4% year-to-date to $254 million, with adjusted operating margin expanding 200 basis points to 25.7% [13][14] - The company raised its full-year revenue guidance to a decline of 1%-3%, reflecting improved performance across Plasma, Blood Center, and Blood Management Technologies [10][11] Q&A Session Summary Question: Can you provide insights on plasma collections and market growth? - Management indicated that share gains and collection volume are driving growth, with double-digit increases in both U.S. and international collections [24][25] Question: What are the expectations for margins moving forward? - Management expects smaller increments in margin improvements in the future, with ongoing focus on operational efficiency [29][30] Question: What is the status of the IVT business and competition? - Management noted that 70% of the decline in IVT was due to specific market disruptions, but they are confident in returning to growth with the right strategies in place [35][36] Question: Can you elaborate on the Vivisure acquisition and its market potential? - The acquisition is seen as a significant opportunity to enhance the company's position in vascular closure, with a focus on a stepwise approach to market entry [44][47] Question: How is the company addressing the challenges in the hospital business? - Management highlighted strong performance in blood management technologies and a focus on stabilizing the IVT segment as key to future growth [81][82]

Core Insights - Haemonetics reported quarterly earnings of $1.31 per share, exceeding the Zacks Consensus Estimate of $1.27 per share, and up from $1.19 per share a year ago [1] - The company achieved a revenue of $338.97 million for the quarter, surpassing the Zacks Consensus Estimate by 1.44%, although this represents a decline from $348.54 million in the same quarter last year [3] Earnings Performance - The earnings surprise for the recent quarter was +3.15%, following a previous surprise of +13.39% when earnings were $1.27 per share against an expectation of $1.12 per share [2] - Haemonetics has consistently surpassed consensus EPS estimates over the last four quarters [2] Stock Performance and Outlook - Haemonetics shares have declined approximately 17.7% since the beginning of the year, contrasting with a 0.5% gain in the S&P 500 [4] - The current consensus EPS estimate for the upcoming quarter is $1.30, with expected revenues of $334.48 million, and for the current fiscal year, the estimate is $4.93 on $1.32 billion in revenues [8] Industry Context - The Medical - Products industry, to which Haemonetics belongs, is currently ranked in the bottom 29% of over 250 Zacks industries, indicating potential challenges for stock performance [9] - Empirical research suggests that trends in earnings estimate revisions are strongly correlated with near-term stock movements, which may impact Haemonetics' future performance [6]

Third Quarter Fiscal 2026 Results February 5, 2026 © 2026 Haemonetics Corporation Q3 Fiscal 2026 Conference Call Detail Conference call will take place at 8:00 a.m. ET on February 5, 2026, and can be accessed via live webcast: Link or teleconference: Link. The earnings release, accompanying slides and a replay of the conference call (beginning at 11:00 AM ET) are available online at www.haemonetics.com. Conference call speakers: Chris Simon President & CEO James D'Arecca EVP, Chief Financial Officer Olga Gu ...

For the quarterly period ended: December 27, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 04-2882273 (State or other jurisdiction of incorporation or organizat ...